OBJECTIVE: To ascertain the progress being made towards the implementation of stereotactic ablative body radiotherapy (SABR) treatment in the UK, to obtain details of current practice in centres with an active treatment programme and to assess the projected future provision. METHODS: In August 2012, an online questionnaire was sent to all 65 UK radiotherapy institutions. The included questions covered the current number of patients being treated and the intended number of patients for each clinical site; immobilization and motion management methods; CT scanning protocols; target and organ-at-risk delineation; treatment planning; image-guidance and treatment protocols; and quality assurance methods. RESULTS: 48/65 (74%) institutions responded by the end of November 2012, with 15 indicating an active SABR programme. A further four centres indicated that a SABR protocol had been established but was not yet in clinical use. 14 of the 29 remaining responses stated an intention to develop a SABR programme in the next 2 years. CONCLUSION: The survey responses confirm that SABR provision in the UK is increasing and that this should be expected to continue in the next 2 years. A projection of the future uptake would suggest that by the end of 2014, UK SABR provision will be broadly in line with international practice.
OBJECTIVE: To ascertain the progress being made towards the implementation of stereotactic ablative body radiotherapy (SABR) treatment in the UK, to obtain details of current practice in centres with an active treatment programme and to assess the projected future provision. METHODS: In August 2012, an online questionnaire was sent to all 65 UK radiotherapy institutions. The included questions covered the current number of patients being treated and the intended number of patients for each clinical site; immobilization and motion management methods; CT scanning protocols; target and organ-at-risk delineation; treatment planning; image-guidance and treatment protocols; and quality assurance methods. RESULTS: 48/65 (74%) institutions responded by the end of November 2012, with 15 indicating an active SABR programme. A further four centres indicated that a SABR protocol had been established but was not yet in clinical use. 14 of the 29 remaining responses stated an intention to develop a SABR programme in the next 2 years. CONCLUSION: The survey responses confirm that SABR provision in the UK is increasing and that this should be expected to continue in the next 2 years. A projection of the future uptake would suggest that by the end of 2014, UK SABR provision will be broadly in line with international practice.
Authors: Mark K Buyyounouski; Robert A Price; Eleanor E R Harris; Robert Miller; Wolfgang Tomé; Tracey Schefter; E Ishmael Parsai; Andre A Konski; Paul E Wallner Journal: Int J Radiat Oncol Biol Phys Date: 2010-04 Impact factor: 7.038
Authors: Chin Loon Ong; Wilko F A R Verbakel; Johan P Cuijpers; Ben J Slotman; Frank J Lagerwaard; Suresh Senan Journal: Radiother Oncol Date: 2010-11-11 Impact factor: 6.280
Authors: Wilko F A R Verbakel; Suresh Senan; Johan P Cuijpers; Ben J Slotman; Frank J Lagerwaard Journal: Radiother Oncol Date: 2009-06-22 Impact factor: 6.280
Authors: Coen W Hurkmans; Johan P Cuijpers; Frank J Lagerwaard; Joachim Widder; Uulke A van der Heide; Danny Schuring; Suresh Senan Journal: Radiat Oncol Date: 2009-01-12 Impact factor: 3.481
Authors: Matthew Beasley; Sean Brown; Helen McNair; Corinne Faivre-Finn; Kevin Franks; Louise Murray; Marcel van Herk; Ann Henry Journal: Br J Radiol Date: 2019-04-24 Impact factor: 3.039
Authors: A Baydoun; H Chen; I Poon; S Badellino; R Dagan; D Erler; M C Foote; A V Louie; K J Redmond; U Ricardi; A Sahgal; T Biswas Journal: Clin Transl Radiat Oncol Date: 2021-10-26
Authors: Lauren Pudsey; Annette Haworth; Paul White; Zoe Moutrie; Benjamin Jonker; Matthew Foote; Joel Poder Journal: Phys Eng Sci Med Date: 2022-02-03